At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Creatine monohydratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
In Brief
A Phase 2 clinical trial evaluating Creatine monohydrate for Huntington's Disease. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess whether biomarkers responsive to creatine in symptomatic individuals are informative in premanifest individuals over a longer duration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedAug 2011
Primary CompletionMay 2013
TodayJul 2026
First PostedAug 8, 2011
Enrollment StartApr 1, 2010
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.9 years ago
Interventions
Creatine monohydratedrug
Up to 30 grams daily creatine monohydrate